Cargando…

Gene expression-based risk score in diffuse large B-cell lymphoma

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma and displays heterogeneous clinical and molecular characteristics. In this study, high throughput gene expression profiling of DLBCL tumor samples was used to design a 12-gene expression–based risk score...

Descripción completa

Detalles Bibliográficos
Autores principales: Bret, Caroline, Klein, Bernard, Moreaux, Jérôme
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681505/
https://www.ncbi.nlm.nih.gov/pubmed/23482333
_version_ 1782273268818903040
author Bret, Caroline
Klein, Bernard
Moreaux, Jérôme
author_facet Bret, Caroline
Klein, Bernard
Moreaux, Jérôme
author_sort Bret, Caroline
collection PubMed
description Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma and displays heterogeneous clinical and molecular characteristics. In this study, high throughput gene expression profiling of DLBCL tumor samples was used to design a 12-gene expression–based risk score (GERS) predictive for patient's overall survival. GERS allowed identifying a high-risk group comprising 46,4% of the DLBCL patients in two independent cohorts (n=414 and n=69). GERS was shown to be an independent predictor of survival when compared to the previously published prognostic factors, including the International Prognostic Index (IPI). GERS displayed a prognostic value in germinal-center B-cell–like subgroup (GCB) and activated B cell–like (ABC) molecular subgroups of patients as well as in DLBCL patients treated with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) or Rituximab-CHOP (R-CHOP) regimens. Combination of GERS and IPI lead to a potent prognostic classification of DLBCL patients. Finally, a genomic instability gene signature was highlighted in gene expression profiles of patients belonging to the high-risk GERS-defined group.
format Online
Article
Text
id pubmed-3681505
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-36815052013-06-17 Gene expression-based risk score in diffuse large B-cell lymphoma Bret, Caroline Klein, Bernard Moreaux, Jérôme Oncotarget Research Papers Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma and displays heterogeneous clinical and molecular characteristics. In this study, high throughput gene expression profiling of DLBCL tumor samples was used to design a 12-gene expression–based risk score (GERS) predictive for patient's overall survival. GERS allowed identifying a high-risk group comprising 46,4% of the DLBCL patients in two independent cohorts (n=414 and n=69). GERS was shown to be an independent predictor of survival when compared to the previously published prognostic factors, including the International Prognostic Index (IPI). GERS displayed a prognostic value in germinal-center B-cell–like subgroup (GCB) and activated B cell–like (ABC) molecular subgroups of patients as well as in DLBCL patients treated with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) or Rituximab-CHOP (R-CHOP) regimens. Combination of GERS and IPI lead to a potent prognostic classification of DLBCL patients. Finally, a genomic instability gene signature was highlighted in gene expression profiles of patients belonging to the high-risk GERS-defined group. Impact Journals LLC 2012-12-31 /pmc/articles/PMC3681505/ /pubmed/23482333 Text en Copyright: © 2012 Bret et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
spellingShingle Research Papers
Bret, Caroline
Klein, Bernard
Moreaux, Jérôme
Gene expression-based risk score in diffuse large B-cell lymphoma
title Gene expression-based risk score in diffuse large B-cell lymphoma
title_full Gene expression-based risk score in diffuse large B-cell lymphoma
title_fullStr Gene expression-based risk score in diffuse large B-cell lymphoma
title_full_unstemmed Gene expression-based risk score in diffuse large B-cell lymphoma
title_short Gene expression-based risk score in diffuse large B-cell lymphoma
title_sort gene expression-based risk score in diffuse large b-cell lymphoma
topic Research Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681505/
https://www.ncbi.nlm.nih.gov/pubmed/23482333
work_keys_str_mv AT bretcaroline geneexpressionbasedriskscoreindiffuselargebcelllymphoma
AT kleinbernard geneexpressionbasedriskscoreindiffuselargebcelllymphoma
AT moreauxjerome geneexpressionbasedriskscoreindiffuselargebcelllymphoma